Rituximab Leads to Faster Response in CLL, But PFS Not Improved

Wayne Kuznar
Published: Monday, Dec 11, 2017

The time to lymphocyte count normalization was significantly shorter in patients randomized to ibrutinib plus rituximab compared with ibrutinib alone (3.0 vs 8.9 months; P <.001). Hemoglobin and platelet counts improved similarly in both groups. According to Burger, there was a trend toward a faster normalization of immunoglobulin levels and T-cell counts in patients on combination therapy, “which may mirror the fact that these patients achieve remissions faster than patients treated with single-agent ibrutinib.” The faster peripheral blood clearance and deeper remissions in patients treated with rituximab plus ibrutinib indicates that ibrutinib does not antagonize rituximab in the clinical setting.

He concluded, “we cannot exclude that longer follow-up of treatment with anti-CD20 antibodies for a longer period of time or with different anti-CD20 antibodies may have a positive impact on PFS and OS.” Reference
Burger JA, Sivina M, Ferrajoli A, et al. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia (CLL). Presented at: American Society of Hematology 59th Annual meeting; December 9-12, 2017; Atlanta, GA. Abstract 427. https://ash.confex.com/ash/2017/webprogram/Paper107661.html.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x